Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
4 clinical trials · Condition
◉ Watch Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
| Record | Firm | Date |
|---|---|---|
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab (NCT07003100) | City of Hope Medical Center | 2024-12-06 |
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome (NCT04652960) | National Cancer Institute (NCI) | 2021-10-21 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment (NCT04541017) | National Cancer Institute (NCI) | 2021-04-06 |
| Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides (NCT03695471) | Mayo Clinic | 2020-02-04 |
Track Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8 automatically
Every clearance here is in the API, with alerts when new ones post.